← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
NMPAR
NMP Acquisition Corp.
Valuation N/A
Financial Services
Price$0.26
Model IV—
P/IV—
Limited data — see page
NMPAU
NMP Acquisition Corp.
Valuation N/A
Financial Services
Price$10.35
Model IV—
P/IV—
Limited data — see page
NMR
NOMURA HOLDINGS INC
Valuation N/A
Financial Services Risk 51 · Elevated
Price$10.65
Model IV—
P/IV—
Limited data — see page
NMRA
Neumora Therapeutics, Inc.
Valuation N/A
Healthcare Risk 41 · Elevated
Price$1.14
Model IV—
P/IV—
Limited data — see page
NMS
Nuveen Minnesota Quality Municipal Income Fund
Valuation N/A
Unknown
Price$10.33
Model IV—
P/IV—
Limited data — see page
NMT
NUVEEN MASSACHUSETTS QUALITY MUNICIPAL INCOME FUND
Valuation N/A
Unknown
Price$11.53
Model IV—
P/IV—
Limited data — see page
NMZ
NUVEEN MUNICIPAL HIGH INCOME OPPORTUNITY FUND
Valuation N/A
Unknown
Price$9.54
Model IV—
P/IV—
Limited data — see page
NNDM
Nano Dimension Ltd.
Valuation N/A
Technology Risk 33 · Moderate
Price$1.53
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
NNNN
Anbio Biotechnology
Valuation N/A
Healthcare Risk 53 · Elevated
Price$6.54
Model IV—
P/IV—
Market implies +34.1%/yr vs model +2.0% · above model
NNOX
Nano-X Imaging Ltd.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.70
Model IV—
P/IV—
Limited data — see page
NNVC
NANOVIRICIDES, INC.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.12
Model IV—
P/IV—
Limited data — see page
NNY
NUVEEN NEW YORK MUNICIPAL VALUE FUND
Valuation N/A
Unknown
Price$7.94
Model IV—
P/IV—
Limited data — see page
NOA
North American Construction Group Ltd.
Valuation N/A
Energy Risk 36 · Moderate
Price$13.40
Model IV—
P/IV—
Limited data — see page
NOAH
NOAH HOLDINGS LTD
Valuation N/A
Financial Services Risk 53 · Elevated
Price$8.14
Model IV—
P/IV—
Market implies +11.9%/yr vs model -7.2% · above model
NOEM
CO2 Energy Transition Corp.
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.69
Model IV—
P/IV—
Limited data — see page
NOEMR
CO2 Energy Transition Corp.
Valuation N/A
Financial Services Risk 39 · Moderate
Price$0.20
Model IV—
P/IV—
Limited data — see page
NOEMU
CO2 Energy Transition Corp.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$12.65
Model IV—
P/IV—
Limited data — see page
NOEMW
CO2 Energy Transition Corp.
Valuation N/A
Financial Services Risk 66 · High
Price$0.12
Model IV—
P/IV—
Limited data — see page
NOK
NOKIA CORP
Valuation N/A
Technology Risk 33 · Moderate
Price$9.65
Model IV—
P/IV—
Limited data — see page
NOMD
Nomad Foods Ltd
Valuation N/A
Consumer Defensive Risk 32 · Moderate
Price$10.93
Model IV—
P/IV—
Limited data — see page
NPAC
New Providence Acquisition Corp. III/Cayman
Valuation N/A
Financial Services
Price$10.48
Model IV—
P/IV—
Limited data — see page
NPACU
New Providence Acquisition Corp. III/Cayman
Valuation N/A
Financial Services
Price$10.59
Model IV—
P/IV—
Limited data — see page
NPACW
New Providence Acquisition Corp. III/Cayman
Valuation N/A
Financial Services
Price$0.27
Model IV—
P/IV—
Limited data — see page
NPCT
Nuveen Core Plus Impact Fund
Valuation N/A
Unknown
Price$9.60
Model IV—
P/IV—
Limited data — see page
NPFD
Nuveen Variable Rate Preferred & Income Fund
Valuation N/A
Unknown
Price$18.24
Model IV—
P/IV—
Limited data — see page
NPKI
NPK International Inc.
Valuation N/A
Technology Risk 49 · Elevated
Price$13.26
Model IV—
P/IV—
Market implies +25.6%/yr vs model -7.4% · above model
NPT
Texxon Holding Ltd
Valuation N/A
Consumer Defensive Risk 35 · Moderate
Price$2.87
Model IV—
P/IV—
Market implies +52.5%/yr vs model +8.0% · above model
NPV
NUVEEN VIRGINIA QUALITY MUNICIPAL INCOME FUND
Valuation N/A
Unknown
Price$10.16
Model IV—
P/IV—
Limited data — see page
NPWR
NET Power Inc.
Valuation N/A
Technology Risk 46 · Elevated
Price$1.93
Model IV—
P/IV—
Market implies +105.4%/yr vs model +15.0% · above model
NRDY
Nerdy Inc.
Valuation N/A
Consumer Defensive Risk 43 · Elevated
Price$9.46
Model IV—
P/IV—
Market implies +72.8%/yr vs model +6.2% · above model
NRGV
Energy Vault Holdings, Inc.
Valuation N/A
Technology Risk 27 · Moderate
Price$4.31
Model IV—
P/IV—
Market implies +29.2%/yr vs model +15.0% · above model
NRIX
Nurix Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$24.83
Model IV—
P/IV—
Market implies +35.5%/yr vs model +29.6% · above model
NRK
NUVEEN NEW YORK AMT-FREE QUALITY MUNICIPAL INCOME FUND
Valuation N/A
Unknown
Price$9.70
Model IV—
P/IV—
Limited data — see page
NRO
NEUBERGER REAL ESTATE SECURITIES INCOME FUND INC
Valuation N/A
Unknown
Price$2.81
Model IV—
P/IV—
Limited data — see page
NRSN
NeuroSense Therapeutics Ltd.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$6.90
Model IV—
P/IV—
Limited data — see page
NRSNW
NeuroSense Therapeutics Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.05
Model IV—
P/IV—
Limited data — see page
NRUC
NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORP /DC/
Valuation N/A
Financial Services
Price$20.43
Model IV—
P/IV—
Limited data — see page
NRXP
NRX Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.40
Model IV—
P/IV—
Market implies +74.4%/yr vs model +15.0% · above model
NRXS
Neuraxis, INC
Valuation N/A
Healthcare Risk 37 · Moderate
Price$5.74
Model IV—
P/IV—
Market implies +32.9%/yr vs model +10.0% · above model
NSRX
Nasus Pharma Ltd
Valuation N/A
Healthcare Risk 27 · Moderate
Price$3.59
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$3.31
Model IV—
P/IV—
Market implies +130.0%/yr vs model +2.0% · above model
NTLA
Intellia Therapeutics, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$11.74
Model IV—
P/IV—
Market implies +53.6%/yr vs model +19.6% · above model
NTNX
Nutanix, Inc.
Valuation N/A
Technology Risk 36 · Moderate
Price$65.92
Model IV—
P/IV—
Market implies -50.0%/yr vs model +14.9% · below model
NTR
Nutrien Ltd.
Valuation N/A
Basic Materials Risk 34 · Moderate
Price$78.72
Model IV—
P/IV—
Limited data — see page
NTRB
NutriBand Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$6.96
Model IV—
P/IV—
Market implies +42.4%/yr vs model +14.6% · above model
NTRBW
NutriBand Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.60
Model IV—
P/IV—
Limited data — see page
NTRP
NextTrip, Inc.
Valuation N/A
Industrials Risk 27 · Moderate
Price$1.80
Model IV—
P/IV—
Market implies +57.8%/yr vs model +2.0% · above model
NTWO
Newbury Street II Acquisition Corp
Valuation N/A
Financial Services Risk 30 · Moderate
Price$10.90
Model IV—
P/IV—
Limited data — see page
NTWOU
Newbury Street II Acquisition Corp
Valuation N/A
Financial Services Risk 43 · Elevated
Price$11.65
Model IV—
P/IV—
Limited data — see page
NTWOW
Newbury Street II Acquisition Corp
Valuation N/A
Financial Services Risk 51 · Elevated
Price$1.15
Model IV—
P/IV—
Limited data — see page
NTZ
NATUZZI S P A
Valuation N/A
Consumer Cyclical Risk 32 · Moderate
Price$1.00
Model IV—
P/IV—
Limited data — see page
NU
Nu Holdings Ltd.
Valuation N/A
Financial Services
Price$14.62
Model IV—
P/IV—
Limited data — see page
NUAI
New ERA Energy & Digital, Inc.
Valuation N/A
Energy Risk 32 · Moderate
Price$5.46
Model IV—
P/IV—
Market implies +71.4%/yr vs model +8.0% · above model
NUAIW
New ERA Energy & Digital, Inc.
Valuation N/A
Energy Risk 44 · Elevated
Price$2.51
Model IV—
P/IV—
Market implies +43.5%/yr vs model +4.0% · above model
NUCL
Eagle Nuclear Energy Corp.
Valuation N/A
Basic Materials Risk 49 · Elevated
Price$6.26
Model IV—
P/IV—
Limited data — see page
NUCLW
Eagle Nuclear Energy Corp.
Valuation N/A
Basic Materials Risk 45 · Elevated
Price$0.69
Model IV—
P/IV—
Limited data — see page
NUTR
NUSATRIP Inc
Valuation N/A
Industrials Risk 52 · Elevated
Price$9.00
Model IV—
P/IV—
Limited data — see page
NUV
NUVEEN MUNICIPAL VALUE FUND INC
Valuation N/A
Unknown
Price$8.52
Model IV—
P/IV—
Limited data — see page
NUVB
Nuvation Bio Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$5.94
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
NUVL
Nuvalent, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$123.96
Model IV—
P/IV—
Limited data — see page